Security
Anebulo Pharmaceuticals, Inc. Common Stock · ANEB
ANEBOTCCommon stockCurrentCIK 1815974Updated Nov 18, 2026
ANEB price & chart
Loading TradingView…
OTC:ANEB on TradingView ↗About the company
Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel solutions for people suffering from cannabis-induced toxicity. Its lead product candidate, selonabant, has completed a Phase 2 clinical trial evaluating its utility in blocking and reversing the negative effects of acute cannabinoid intoxication in healthy adults challenged with oral THC. Rather than proceeding directly with Phase 3 studies of oral selonabant in adults with ACI, the Company is prioritizing the advancement of a selonabant IV formulation as a potential treatment for pediatric patients with acute cannabis-induced toxicity, which it believes offers the potential for a faster timeline to approval relative to the adult oral product. Anebulo has scaled up the intravenous formulation for initial clinical safety studies, and initiated a Phase 1 SAD study of IV selonabant in September 2025. Selonabant is a competitive antagonist at the human CB1 receptor. For further information about Anebulo, please visit www.anebulo.com.
In the news
No coverage from other publishers is available.
Recent filings
15-12G filing
25 filing
SCHEDULE 13G/A - filed by Nantahala Capital Management, LLC regarding Anebulo Pharmaceuticals, Inc.
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Other Events
Items 3.01, 8.01, 9.01
SC 13E3/A - filed by Anebulo Pharmaceuticals, Inc. regarding Anebulo Pharmaceuticals, Inc.
Other Events
Items 8.01, 9.01
SC 13E3/A - filed by Anebulo Pharmaceuticals, Inc. regarding Anebulo Pharmaceuticals, Inc.
Other Events
Items 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 14,008,484Source | 5,995,635Source | 9,421,997Source | 15,841,220Source | 7,500,773Source | 10,701,039Source | 2,467,940Source | 9,047,884Source | 12,145,616Source | 4,073,114Source | 11,670,151Source | 15,579,431Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 13,279,901Source | 5,147,139Source | 9,041,570Source | 14,998,467Source | 6,644,517Source | 10,354,773Source | 1,404,211Source | 8,520,578Source | 11,627,849Source | 3,094,200Source | — | — |
| Assets, CurrentUSD | 13,807,935Source | 5,370,815Source | 9,273,766Source | 15,395,489Source | 6,816,257Source | 10,535,369Source | 1,962,513Source | — | 11,962,506Source | 3,507,990Source | — | — |
| Other Assets, NoncurrentUSD | 200,549Source | 624,820Source | 148,231Source | 445,731Source | 684,516Source | 165,670Source | 505,427Source | — | 183,110Source | 565,124Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 546,032Source | 1,010,321Source | 1,485,646Source | 878,799Source | 1,013,556Source | 963,821Source | 569,225Source | 716,560Source | 487,688Source | 260,583Source | 1,068,801Source | 512,531Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 41,086Source | 25,934Source | 41,086Source | 41,086Source | 25,934Source | 41,086Source | 25,934Source | 25,634Source | 41,086Source | 25,934Source | 25,634Source | 23,345Source |
| Additional Paid in CapitalUSD | 85,165,045Source | 69,013,155Source | 85,941,523Source | 84,988,845Source | 68,861,516Source | 85,742,993Source | 69,477,261Source | 67,988,554Source | 85,505,349Source | 69,190,341Source | 67,777,757Source | 60,513,258Source |
| Retained Earnings (Accumulated Deficit)USD | -71,743,679Source | -64,053,775Source | -78,046,258Source | -70,067,510Source | -62,400,233Source | -76,046,861Source | -67,604,480Source | -59,682,864Source | -73,888,507Source | -65,403,744Source | -57,202,041Source | -45,469,703Source |
| Stockholders' Equity Attributable to ParentUSD | 13,462,452Source | 4,985,314Source | 7,936,351Source | 14,962,421Source | 6,487,217Source | 9,737,218Source | 1,898,715Source | 8,331,324Source | 11,657,928Source | 3,812,531Source | 10,601,350Source | 15,066,900Source |
| Liabilities and EquityUSD | 14,008,484Source | 5,995,635Source | 9,421,997Source | 15,841,220Source | 7,500,773Source | 10,701,039Source | 2,467,940Source | 9,047,884Source | 12,145,616Source | 4,073,114Source | 11,670,151Source | 15,579,431Source |
| Current liabilities: | ||||||||||||
| Accounts Payable, CurrentUSD | 427,578Source | 384,920Source | 554,862Source | 319,515Source | 318,679Source | 607,539Source | 252,142Source | 565,949Source | 224,175Source | 156,426Source | 534,545Source | 380,828Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 118,454Source | 625,401Source | 930,784Source | 559,284Source | 694,877Source | 356,282Source | 317,083Source | 150,611Source | 263,513Source | 104,157Source | 534,256Source | 131,703Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 300,000Source | 200,000Source | 198,530Source | 564,333Source | 237,644Source | 286,920Source | 1,446,824Source | 758,884Source | 884,723Source | 480,661Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 383,364Source | 95,716Source | 67,749Source | -378,119Source | 153,717Source | 270,780Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,273,076Source | -1,689,989Source | -6,349,687Source | -8,090,849Source | -9,683,133Source | -5,437,174Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 14,883,336Source | -62,354Source | 6,382,065Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -1,273,076Source | -1,689,989Source | 8,533,649Source | -8,153,203Source | -3,301,068Source | -5,437,174Source |
| Additional Financial Items | ||||||||||||
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | 17,440Source | 59,697Source | 382,014Source | 151,230Source | — | — |
| General and Administrative ExpenseUSD | — | — | 1,253,998Source | 915,912Source | 1,455,173Source | 1,367,616Source | 1,450,269Source | 1,097,265Source | 4,923,540Source | 4,759,818Source | 6,183,402Source | 3,869,636Source |
| InterestExpenseNonoperatingUSD | — | — | 245,182Source | 59,696Source | 17,439Source | 59,696Source | 17,439Source | 59,697Source | 382,014Source | 151,230Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,676,169Source | -1,653,542Source | -1,999,397Source | -2,463,030Source | -2,158,354Source | -2,200,736Source | -8,484,763Source | -8,201,703Source | -11,732,338Source | -6,825,619Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -6,825,619Source |
| Nonoperating Income (Expense)USD | — | — | 216,153Source | 10,709Source | 620,513Source | 125,121Source | 101,906Source | 211,388Source | 738,718Source | 107,052Source | 51,261Source | 5,555Source |
| Operating ExpensesUSD | — | — | 1,892,322Source | 1,664,251Source | 2,619,910Source | 2,588,151Source | 2,260,260Source | 2,412,124Source | 9,223,481Source | 8,308,755Source | 11,783,599Source | 6,831,174Source |
| Other Nonoperating Income (Expense)USD | — | — | -528Source | 2,321Source | -34Source | 47Source | -96Source | -283Source | -1,195Source | 9,260Source | -41,146Source | -1,777Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | 116,664Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 15,000,000Source | — | 6,646,748Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | 52,400Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -1,892,322Source | -1,664,251Source | -2,619,910Source | -2,588,151Source | -2,260,260Source | -2,412,124Source | -9,223,481Source | -8,308,755Source | -11,783,599Source | -6,831,174Source |
| Other Nonoperating Income (Expense)USD | — | — | -528Source | 2,321Source | -34Source | 47Source | -96Source | -283Source | -1,195Source | 9,260Source | -41,146Source | -1,777Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,676,169Source | -1,653,542Source | -1,999,397Source | -2,463,030Source | -2,158,354Source | -2,200,736Source | -8,484,763Source | -8,201,703Source | -11,732,338Source | -6,825,619Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.04Source | -0.06Source | -0.05Source | -0.09Source | -0.05Source | -0.08Source | -0.25Source | -0.32Source | 0.47Source | -0.29Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.04Source | -0.06Source | -0.05Source | -0.09Source | -0.05Source | -0.08Source | -0.25Source | -0.32Source | 0.47Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 41,084,731Source | 25,933,217Source | 41,084,731Source | 27,415,430Source | 41,084,731Source | 25,933,217Source | 33,820,306Source | 25,822,258Source | 25,074,481Source | 23,344,567Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 41,084,731Source | 25,933,217Source | 41,084,731Source | 27,415,430Source | 41,084,731Source | 25,933,217Source | 33,820,306Source | 25,822,258Source | 25,074,481Source | — |
| Interest Expense (non-operating)USD | — | — | 245,182Source | 59,696Source | 17,439Source | 59,696Source | 17,439Source | 59,697Source | 382,014Source | 151,230Source | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 1,253,998Source | 915,912Source | 1,455,173Source | 1,367,616Source | 1,450,269Source | 1,097,265Source | 4,923,540Source | 4,759,818Source | 6,183,402Source | 3,869,636Source |
| Interest ExpenseUSD | — | — | 100,000Source | 59,696Source | 17,000Source | 100,000Source | 17,000Source | 100,000Source | 400,000Source | — | — | — |
| Interest Income, OtherUSD | — | — | 102,257Source | 68,084Source | 85,410Source | 7,067Source | 109,616Source | 26,006Source | 257,913Source | 249,022Source | 92,407Source | 7,332Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -6,825,619Source |
| Nonoperating Income (Expense)USD | — | — | 216,153Source | 10,709Source | 620,513Source | 125,121Source | 101,906Source | 211,388Source | 738,718Source | 107,052Source | 51,261Source | 5,555Source |
| Operating ExpensesUSD | — | — | 1,892,322Source | 1,664,251Source | 2,619,910Source | 2,588,151Source | 2,260,260Source | 2,412,124Source | 9,223,481Source | 8,308,755Source | 11,783,599Source | 6,831,174Source |
| Research and Development ExpenseUSD | — | — | 638,324Source | 748,339Source | 1,164,737Source | 1,220,535Source | 809,991Source | 1,314,859Source | 4,299,941Source | 3,548,937Source | 5,600,197Source | 2,961,538Source |
| Investment Income, Net | — | — | — | —Source | — | — | — | — | — | — | — | — |
Filing attachments
ex99-1.htm · 8-K · 2026-02-12
Exhibit 99.1 Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates AUSTIN, Texas (February 12, 2026) - Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2025, and recent updates. Second Quarter Fiscal Year 2026 and Subs…
Read attachment ↗ex99-1.htm · 8-K · 2026-02-06
Exhibit 99.1 Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC AUSTIN, Texas (February 6, 2026) - Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that the Company’s board of directors (the “Board”) has approved the voluntary delisting of the Company’s common stock from Th…
Read attachment ↗ex99-1.htm · 8-K · 2026-01-29
Exhibit 99.1 Anebulo Pharmaceuticals Announces Final Results of Tender Offer AUSTIN, Texas (January 29, 2026) - Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced the final results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 per share (“Common Stock”), which expired one …
Read attachment ↗ex99-1.htm · 8-K · 2026-01-27
Exhibit 99.1 Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer AUSTIN, Texas (January 27, 2026) - Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced the preliminary results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 per share (“Common Stock”), which …
Read attachment ↗ex99-1.htm · 8-K · 2025-12-22
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer AUSTIN, Texas (December 22, 2025) - Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that the Board of Directors has decided to commence a cash tender offer as part of its plan to “go private” in lieu o…
Read attachment ↗ex99-1.htm · 8-K · 2025-11-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates AUSTIN, Texas (November 13, 2025) - Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended September 30, 2025, and recent updates. First Q…
Read attachment ↗